Showing papers by "Jeffrey L. Lennox published in 2009"
TL;DR: Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients and has rapid and potent antiretroviral activity, which was non-inferior to that of efvirenz at week 48.
593 citations
TL;DR: Among vulnerable populations during an influenza pandemic are persons with or at risk for HIV infection, tuberculosis, or chronic viral hepatitis, and existing infrastructure should be expanded and pandemic planning should include preparations to reduce the risks.
Abstract: Among vulnerable populations during an influenza pandemic are persons with or at risk for HIV infection, tuberculosis, or chronic viral hepatitis. HIV-infected persons have higher rates of hospitalization, prolonged illness, and increased mortality from influenza compared with the general population. Persons with tuberculosis and chronic viral hepatitis may also be at increased risk of morbidity and mortality from influenza because of altered immunity and chronic illness. These populations also face social and structural barriers that will be exacerbated by a pandemic. Existing infrastructure should be expanded and pandemic planning should include preparations to reduce the risks for these populations.
18 citations
TL;DR: Owing to recently published data raising the possibility of an association between abacavir and heart disease, as well as data regarding efficacy in patients with higher HIV RNA levels, ABC/3TC has now been listed as an alternative NRTI backbone in the latest USA Department of Health and Human Services guidelines.
Abstract: HIV infection remains a common cause of morbidity and mortality worldwide. Fortunately, patients treated with combination antiretroviral therapy (ART) have significantly improved survival rates and quality of life. The standard of care for the treatment of ART-naive patients includes three drugs, two of which should be nucleoside reverse transcriptase inhibitors (NRTIs). Abacavir/lamivudine (ABC/3TC) is a fixed dose combination NRTI tablet that has been approved as an NRTI backbone. ABC/3TC is among the NRTI combinations that are recommended as first line in the most recent International AIDS Society–USA guidelines and WHO European Region protocol. However, owing to recently published data raising the possibility of an association between abacavir and heart disease, as well as data regarding efficacy in patients with higher HIV RNA levels, ABC/3TC has now been listed as an alternative NRTI backbone in the latest USA Department of Health and Human Services guidelines. While ABC has been associated with a h...
2 citations
01 Jan 2009
TL;DR: Among vulnerable populations during an influenza pandemic are persons with or at risk for HIV infection, tuberculosis, or chronic viral hepatitis, who are at increased risk of morbidity and mortality from influenza.
Abstract: Among vulnerable populations during an influenza pandemic are persons with or at risk for HIV infection, tuberculosis,orchronicviral hepatitis. HIV-infectedpersonshave higher rates of hospitalization, prolonged illness, and increased mortality from influenza compared with the general population. Persons with tuberculosis and chronic viral hepatitis may also be at increased risk of morbidity and mortality from influenza because of